# EDGAR Filing Document

**Accession Number:** 0001841258
**File Stem:** 0000950103-23-004000
**Filing Date:** 2023-3
**Character Count:** 3183
**Document Hash:** 2052e4134f4ff41dce8630bcd09d3139
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-004000.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000950103-23-004000

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**EFFECTIVENESS DATE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** European Biotech Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001841258
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40211
- **FILM NUMBER:** 23727378

**BUSINESS ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK BUILDING
- **CITY:** LAUSANNE
- **STATE:** V8
- **ZIP:** 1015
- **BUSINESS PHONE:** 41 77 976 21 09

**MAIL ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK BUILDING
- **CITY:** LAUSANNE
- **STATE:** V8
- **ZIP:** 1015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION<br> UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934<br> OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number:** **001-40211**

**EUROPEAN BIOTECH ACQUISITION CORP.**<br> (Exact name of registrant as specified in its charter)

**EPFL Innovation Park Building**

**3e Route J-D. Colladon**

**CH-1015 Lausanne**

**Switzerland**

**+41 77 976 21 09**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Units, each consisting of one Class A Ordinary Share and one-third of one redeemable warrant<br> Class A Ordinary Shares, $0.0001 par value per share**

**Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 0

Pursuant to the requirements of the Securities Exchange Act of 1934, Oculis Merger Sub II Company, as successor by merger to European Biotech Acquisition Corp., has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

[*Signature page follows*]

---

| | | |
|:---|:---|:---|
|  | **Oculis Merger Sub II Company**<br>(as successor by merger to European Biotech Acquisition Corp.) | **Oculis Merger Sub II Company**<br>(as successor by merger to European Biotech Acquisition Corp.) |
| Date: March 13, 2023 | By: | /s/ Riad Sherif |
|  | Name: | Riad Sherif |
|  | Title: | Authorized Signatory |

---